Intensive insulin therapy and pentastarch resuscitation in severe sepsis.

By F. Brunkhorst, C. Engel, F. Bloos, A. Meier‑Hellmann, M. Ragaller, N. Weiler, O. Moerer, M. Gruendling, M. Oppert, S. Grond and 13 more. New England Journal of Medicine, 2008

2,799 citations recorded by the source corpus.

Subfields: Critical Care and Intensive Care Medicine, Endocrinology, Diabetes and Metabolism, Epidemiology

View Paper: https://www.semanticscholar.org/paper/5e29d0f35fb07238a65438d0f2ef009eff791e11

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Critical Care and Intensive Care Medicine

In Endocrinology, Diabetes and Metabolism

In Epidemiology

Citations in the corpus

Ill Adults: A Meta-analysis Benefits and Risks of Tight Glucose Control in Critically (2010, methodology): “The study participants encompass a broad distribution of adult ICU patients, as indicated by the variety of mean ages (46-75 years), distributions by sex (31%-95% men), proportions of patients with diabetes (0%100%), and degree of disease severity as measured by mean Acute Physiology and Chronic Hea”
Diagnosis and Management of Complicated Intra-Abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America (2010, neutral): “Further information on pediatric dosing can be obtained elsewhere [187–189].”
Long-term complications of critical care (2011, background): “However, in separate studies, it has also been associated with increased rates of hypoglycemia and 90-day mortality (44, 45).”
KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. (2013, background): “In addition, we noted that there appears to be harm with starch-containing fluids.(32-36) Therefore, these solutions should be avoided in patients at risk of AKI or with AKI.”
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012 (2013, background): “(This recommendation is based on the results of the VISEP [128], CRYSTMAS [122], 6S [123], and CHEST [124] trials.”